Avadel specializes in innovative patient solutions.
At Avadel Pharmaceuticals plc (Nasdaq: AVDL) we are focused on providing solutions for overlooked and unmet medical needs through patient-focused, innovative products. Avadel is specialty pharmaceutical company passionately committed to serving provider, patients, and the community. We are thoughtful in our approach to identifying unmet needs and dedicated to addressing highly-bothersome and chronic conditions with limited treatment options. In 2018, Avadel launched Noctiva™, the first and only FDA approved product for nocturia due to nocturnal polyuria.
Our current portfolio of products and product candidates focus on urology, sleep medicine / CNS, and sterile injectable products. Avadel is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France. For more information, visit www.avadel.com. Follow us on Twitter at www.twitter.com/AvadelPharma